ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 7
Health Care Resource Utilization and Transition of Care
Panelists discuss routine laboratory monitoring for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) as well as insights from the American Society of Hematology Annual Meeting and Exposition (ASH 2024) data on health care resource utilization and costs associated with administering chimeric antigen receptor (CAR) T-cell therapy and managing related toxicities.
Video content above is prompted by the following:
Dr. O’Dwyer to Dr. Shaughnessy: What labs do you routinely monitor for CRS and ICANS, and how frequently?
Dr. O’Dwyer to Dr. Logan: One of the related aspects of CAR T-cell therapy is health care resource utilization and cost associated with not only administering CAR T-cell therapy but managing CRS and ICANS. Dr. Logan, can you share key highlights from the data you and your colleagues presented at ASH this year?
Related Content:
